Glenmark Pharmaceuticals PAT at Rs 354.49 crore in September quarter

Glenmark Pharmaceuticals Ltd connected Thursday reported a consolidated nett aft taxation of Rs 354.49 crore successful the 2nd 4th ended connected September 30, 2024. The institution reported a consolidated nonaccomplishment aft taxation of Rs 180.3 crore successful the aforesaid 4th past fiscal, Glenmark Pharmaceuticals said successful a regulatory filing.

Consolidated full gross from operations successful the 2nd 4th stood astatine Rs 3,433.8 crore against Rs 3,207.37 crore successful the year-ago period.

Total expenses successful the 4th nether reappraisal were Rs 3,000.64 crore compared to Rs 3,008 crore successful the corresponding play a twelvemonth ago.

"This quarter, we person maintained a beardown maturation trajectory, driven by robust performances successful the Indian and European markets. Our flagship respiratory brand, RYALTRIS, continues to execute good crossed each cardinal regions, reaffirming its presumption arsenic a starring attraction option," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

Additionally, helium said, "We person strategically in-licensed innovative products successful our precedence therapeutic areas, further strengthening our committedness to addressing unmet aesculapian needs and improving diligent outcomes." Sales from the formulation concern successful India successful Q2 FY25 was Rs 1,281.7 crore against Rs 1,125.2 crore successful the erstwhile corresponding quarter, a maturation of 13.9 per cent, the institution said.

North America registered gross from the income of finished dosage formulations of Rs 740.5 crore successful the 2nd 4th implicit gross of Rs 749.8 crore successful the year-ago period.

Glenmark's European operations gross for the 2nd 4th of FY 2024-25, was Rs 687.4 crore from Rs 599.7 crore successful the year-ago period, the institution said.